Plain-English translation of NCT07660627 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a sensitive blood test can detect circulating tumor DNA—genetic material from cancer cells in your bloodstream—to identify cancer recurrence earlier than standard imaging scans. Researchers will collect blood samples from patients with esophageal, gastric, or pancreatic cancer at different points during and after treatment to see if this DNA test can predict which patients might have cancer returning. The goal is to help doctors catch cancer recurrence sooner, when treatment may be more effective.
After treatment, some cancer may remain in the body too small to see on regular scans—a condition called minimal residual disease. This trial exists because detecting the medication's effectiveness and catching cancer recurrence earlier could help doctors change treatment plans faster and improve outcomes for patients.
You likely qualify if…
You likely don't qualify if…
You will have blood drawn several times: before your cancer treatment starts, at the time of surgery (if applicable), and then roughly every 3 months for 1–2 years afterward, or until your cancer returns. Each blood sample is analyzed in the laboratory to measure tumor DNA and track how it changes over time. This helps researchers understand whether the blood test can reliably predict treatment response and cancer recurrence.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
Czechia